<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11546">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956629</url>
  </required_header>
  <id_info>
    <org_study_id>3682-041</org_study_id>
    <secondary_id>2016-003227-37</secondary_id>
    <nct_id>NCT02956629</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of MK-3682 + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)</brief_title>
  <official_title>A Phase 2, Open-Label Clinical Trial to Study the Efficacy and Safety of 12 Weeks of the Combination Regimen of MK-3682 + Ruzasvir in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 3, 4, 5 or 6 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a nonrandomized, multi-site, open-label trial to evaluate a novel two-drug
      combination regimen (MK-3682 450 mg + ruzasvir [RZR; MK-8408] 180 mg once daily [q.d.] for
      12 weeks) in male and female treatment-naïve (TN) or treatment-experienced (TE) participants
      with chronic hepatitis C virus (HCV) infection genotype (GT) GT1, GT2, GT3, GT4, GT5, or GT6
      who have not previously received HCV direct-acting antiviral (DAA) therapy. Cirrhotic (C)
      and non-cirrhotic (NC) participants with and without human immunodeficiency virus (HIV)
      co-infection will be enrolled.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Any GT that meets virologic futility criteria will be given the option of extending
      treatment with MK-3682 + RZR to 16 weeks with ribavirin (RBV) added.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with sustained virologic response (SVR) 12 weeks after completing study therapy (SVR12)</measure>
    <time_frame>12 weeks after completing study therapy (Week 24)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing an adverse event (AE)</measure>
    <time_frame>Up to Week 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing an AE of clinical importance</measure>
    <time_frame>Up to Week 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing a severe adverse event (SAE)</measure>
    <time_frame>Up to Week 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing a drug-related AE</measure>
    <time_frame>Up to Week 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants experiencing a drug-related SAE</measure>
    <time_frame>Up to Week 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of participants discontinuing study therapy due to an AE</measure>
    <time_frame>Up to Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with SVR 24 weeks after completing study therapy (SVR24)</measure>
    <time_frame>24 weeks after completing study therapy (Week 36)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with virologic failure</measure>
    <time_frame>Up to Week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Arm 1: HCV GT1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female participants with HCV GT1a infection take MK-3682 450 mg + RZR 180 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: HCV GT1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female participants with HCV GT1b infection take MK-3682 450 mg + RZR 180 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: HCV GT2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female participants with HCV GT2 infection take MK-3682 450 mg + RZR 180 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: HCV GT3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female participants with HCV GT3 infection take MK-3682 450 mg + RZR 180 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5: HCV GT4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female participants with HCV GT4 infection take MK-3682 450 mg + RZR 180 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6: HCV GT5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female participants with HCV GT5 infection take MK-3682 450 mg + RZR 180 mg for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7: HCV GT6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Male and female participants with HCV GT6 infection take MK-3682 450 mg + RZR 180 mg for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3682</intervention_name>
    <description>Participants take 3 tablets each containing 150 mg MK-3682 q.d. by mouth.</description>
    <arm_group_label>Arm 1: HCV GT1a</arm_group_label>
    <arm_group_label>Arm 2: HCV GT1b</arm_group_label>
    <arm_group_label>Arm 3: HCV GT2</arm_group_label>
    <arm_group_label>Arm 4: HCV GT3</arm_group_label>
    <arm_group_label>Arm 5: HCV GT4</arm_group_label>
    <arm_group_label>Arm 6: HCV GT5</arm_group_label>
    <arm_group_label>Arm 7: HCV GT6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruzasvir</intervention_name>
    <description>Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.</description>
    <arm_group_label>Arm 1: HCV GT1a</arm_group_label>
    <arm_group_label>Arm 2: HCV GT1b</arm_group_label>
    <arm_group_label>Arm 3: HCV GT2</arm_group_label>
    <arm_group_label>Arm 4: HCV GT3</arm_group_label>
    <arm_group_label>Arm 5: HCV GT4</arm_group_label>
    <arm_group_label>Arm 6: HCV GT5</arm_group_label>
    <arm_group_label>Arm 7: HCV GT6</arm_group_label>
    <other_name>MK-8408</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin</intervention_name>
    <description>RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on MK-3682 + RZR alone.</description>
    <arm_group_label>Arm 1: HCV GT1a</arm_group_label>
    <arm_group_label>Arm 2: HCV GT1b</arm_group_label>
    <arm_group_label>Arm 3: HCV GT2</arm_group_label>
    <arm_group_label>Arm 4: HCV GT3</arm_group_label>
    <arm_group_label>Arm 5: HCV GT4</arm_group_label>
    <arm_group_label>Arm 6: HCV GT5</arm_group_label>
    <arm_group_label>Arm 7: HCV GT6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  has HCV RNA (≥10,000 IU/mL in peripheral blood) at the time of screening

          -  has documented chronic HCV GT1, GT2, GT3, GT4, GT5, or GT6 (with no evidence of
             non-typeable or mixed GT)

          -  is a female who is not of reproductive potential, or is a female of reproductive
             potential who agrees to avoid becoming pregnant from two weeks prior to Day 1 through
             14 days after the last dose of study drug via abstinence or use of two approved
             contraceptives

          -  is C or NC

          -  if coinfected with HIV, has documented HIV infection prior to Day 1, and either does
             not use an antiretroviral therapy (ART) or has well-controlled HIV on stable ART (at
             least 4 weeks prior to study entry)

        Exclusion Criteria:

          -  has evidence of decompensated liver disease

          -  is C and is Child-Pugh Class B or C, or has a Child-Tucotte-Pugh score &gt;6

          -  is coinfected with hepatitis B virus (hepatitis B surface antigen or hepatitis B core
             antibody positive)

          -  is coinfected with HIV and has a recent (within 6 months prior to screening)
             opportunistic infection

          -  has a history of malignancy other than adequately treated basal cell or squamous cell
             skin cancer or in situ cervical cancer or carcinoma in situ within 5 years of signing
             informed consent

          -  is C and has evidence (liver imaging within 6 months prior to Day 1) of
             hepatocellular carcinoma (HCC) or is under evaluation for HCC

          -  has participated in another investigational drug study within 30 days of signing
             informed consent

          -  is a female who is pregnant or breastfeeding or expecting to conceive or donate eggs
             from Day 1 through 6 months after the last dose of study drug or longer if dictated
             by local regulations, or is a male subject who is expecting to donate sperm from Day
             1 through 14 days after the last dose of study drug or longer if dictated by local
             regulations, or is a male whose female partner(s) is/are pregnant or breastfeeding

          -  has clinically relevant alcohol or drug abuse within 12 months of screening

          -  has any of the following conditions: organ transplants other than cornea and hair;
             poor venous access; history of gastric surgery; clinically significant cardiac
             abnormality/dysfunction; any major medical condition which, in the opinion of the
             investigator, might interfere with participation; hospitalization within 3 months
             prior to enrollment; any condition that might require hospitalization; any condition
             requiring or likely to require chronic systemic administration of corticosteroids,
             tumor necrosis factor (TNF) antagonists, or immunosuppressant drugs; a
             life-threatening serious adverse event (SAE) during screening; or hepatitis not
             caused by HCV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Toll Free Number</last_name>
    <phone>1-888-577-8839</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0019)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0018)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0021)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0022)</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0025)</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Call for Information (Investigational Site 0006)</name>
      <address>
        <city>Novi</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme</name>
      <address>
        <city>North Ryde</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Australian Medical Information Centre</last_name>
      <phone>61 2 8988 8428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Canada</name>
      <address>
        <city>Kirkland</city>
        <state>Quebec</state>
        <zip>H9H 4M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Medical Information Centre Centre d'information medicale Merck Canada Inc.</last_name>
      <phone>514-428-8600 / 1-800-567-2594</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Co. Ltd.</name>
      <address>
        <city>Hod Hasharon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gally Teper</last_name>
      <phone>972-9-9533310</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme (New Zealand) Ltd.,</name>
      <address>
        <city>Wellington</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Australian Medical Information Centre</last_name>
      <phone>61 2 8988 8428</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>MSD Polska Sp. Z o.o.</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Johansson</last_name>
      <phone>48 22ý478 43 24</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp and Dohme de Espana S.A.</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joaquin Mateos Chacon</last_name>
      <phone>(0034) 913210600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Merck Sharp &amp; Dohme Ltd.</name>
      <address>
        <city>Hoddesdon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Toms</last_name>
      <phone>+44 (0) 1992 452475</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Israel</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>November 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
